« Ranolazine Safe But Adds No Benefit for Non-ST Elevation ACS - MedPage Today
Drug Works for Chest Pain but Doesn't Save Lives - Ivanhoe »

CVT Continues its Spending Spree - Motley Fool

CVT Continues its Spending Spree
Motley Fool -10 hours ago
CVT's only marketed compound is the angina treatment Ranexa. In the first quarter, CVT announced clinical trial results for Ranexa that sent shares …

More: continued here

This entry was posted on Wednesday, April 25th, 2007 at 10:04 pm and is filed under Angina. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

Leave a Reply

You must be logged in to post a comment.